Bird & Bird advises the Dementia Discovery Fund on its investment into Amphista Therapeutics

Contacts

james baillieu module
James Baillieu

Partner
UK

I'm co-head of our London corporate team where I have over 20 years' experience advising clients on corporate transactions, including mergers and acquisitions (and disposals), equity capital markets transactions, private equity and venture capital investments/exits, joint ventures and corporate reorganisations.

adam meisels Module
Adam Meisels

Partner
UK

I am a partner in the Corporate team and am based in our London office. I advise clients on a range of corporate transactions with a particular focus on Venture Capital and Mergers & Acquisitions, predominantly involving technology companies.

International law firm Bird & Bird has advised the Dementia Discovery Fund (DDF) on its Series B extension investment into Amphista Therapeutics.

The DDF is a specialist venture capital fund, managed by SV Health Managers, that invests in, and creates, new biotech companies delivering transformational therapeutics for dementia. The DDF is backed by leading pharmaceutical companies (Biogen, Eli Lilly and Co., GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), along with AARP, Aegon, Bill Gates, British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, the UK Government’s Department of Health and Social Care, and the charity Alzheimer’s Research UK.

Amphista is a leader in identifying and advancing next generation targeted protein degradation (TPD) approaches to develop a new generation of innovative therapies with significantly improved efficacy. The investment is in recognition of the progress made in relation to Amphista’s Eclipsys™ platform and its potential to enable therapies to treat diseases of the central nervous system, with a focus on neurodegeneration.

The investment will enable Amphista to accelerate the application of its technology into indications largely inaccessible using traditional TPD approaches and will enable further pre-clinical development with a focus on diseases of the central nervous system, particularly dementia.

The Bird & Bird team was led by James Baillieu (partner, Corporate) and included Adam Meisels (senior associate, Corporate) and Dean Rae (associate, Corporate), Sally Shorthose (partner, Intellectual Property and co-head of International Life Sciences Regulatory Group), Pieter Erasmus (associate, Intellectual Property and member of International Life Sciences Regulatory Group) and Penny Hunt (legal director, Employment).

James Baillieu, partner in the Corporate practice at Bird & Bird comments: “We were delighted to support DDF on this exciting transaction which is a fantastic example of the excellent work carried out by our life sciences and venture capital practices.”

News & Deals

More News & Deals
News Bird & Bird advises MOL on joint acquisition of Scotland's Port of Nigg

Sep 11 2025

Read More
News Bird & Bird hires industrials, infrastructure and transport expert Eleanor Kerslake as new partner

Sep 08 2025

Read More
Deal Bird & Bird advises Siloco on the acquisition of NOVOCONT and NOVORENT

Sep 05 2025

Read More
Deal Bird & Bird advises Investronic shareholders on Evolem's equity investment

Sep 03 2025

Read More
News Bird & Bird strengthens Polish Energy & Utilities team with new partner hire

Sep 02 2025

Read More
News Bird & Bird boosts regulatory team in Brussels with double partner hire

Sep 01 2025

Read More